Impact and predictors of outcome of COVID-19 in pulmonary hypertension patients

Y. M. A. Soliman1, R. I. M. Elkorashy1, Ahmed Abdel Aziz2, Asmaa Abdelnaby3 and Sally Magdy1*

Abstract

Background: The pandemic had a significant impact on those with underlying chronic health conditions being at risk of developing a more severe disease with rapid progression, significant complications, and with increased risk of mortality.

This was also expected in the pulmonary vascular community owing to the vulnerable nature of this population, who are characterized by an increase in the pulmonary vascular resistance leading to right heart failure.

This study is aiming to identify the incidence of COVID-19 infection among pulmonary hypertension patients receiving specific therapy as well as the predictors of the COVID-19 disease severity and outcome in those patients.

Results: Data analysis of 197 PAH and CTEPH patients, showed that the incidence of SARS-CoV-2 infection is 10.66% (n = 21). Seven patients (33.3%) required hospitalization. Mortality rate is 14.3% (3/21).

Severity of COVID19 disease in those patients has statistically significant moderate to strong correlation with higher values of d-dimer (r = 0.821, P = 0.000), ferritin (r = 0.718, p = 0.000), CRP (r = 0.613, p = 0.04), acute renal failure (r = 0.557, p = 0.009), and hypoxemia (r = 0.825, p = 0.000).

Mortality from COVID-19 show moderate to strong statistically significant correlations with acute renal failure (r = 0.795, p = 0.000), hypoxemia (r = 0.645, p = 0.002), higher values of ferritin (r = 0.689, p = 0.001) and d-dimer (r = 0.603, P = 0.004).

Conclusions: COVID-19 in PAH and CTEPH patients is challenging, higher COVID-19 infection rate is present in those patients and is associated with increased disease severity and higher mortality.

Keywords: Pulmonary hypertension, COVID-19, Impact, Predictors

Introduction and rationale

From the time of emergence of COVID-19 in December 2019, [1] there has been unique challenges facing the healthcare system when dealing with patients with underlying health conditions infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as they are at increased risk for poor outcome [2].

The pandemic had a significant impact on those with underlying chronic health conditions being at risk of developing a more severe disease with rapid progression, significant complications, and with increased risk of mortality [3].

This was also expected in the pulmonary vascular community owing to the vulnerable nature of this population, who are characterized by an increase in the pulmonary vascular resistance leading to right heart failure [4].
Putting into consideration the lung injury inflicted via the COVID-19 disease [5] highlights the vulnerability of those patients more than others, as they are probably a main contributor to both morbidity and mortality related to COVID-19 disease.

However, data collected early in the pandemic from pulmonary arterial hypertension (PAH) centers worldwide observed paucity in reported PAH patients infected with COVID-19, and a perceived low risk for severe COVID-19 in PAH patients with an unexpectedly favorable clinical outcome. Multiple clarifications were proposed, some elucidated that the disease itself might be protective against COVID-19, this is suggested by autopsy findings of SARS-CoV-2 infecting endothelial cells with associated vascular injury, thrombosis, and the reduced angiotensin converting enzyme 2 (ACE2) expression that plays a role in reducing the cytokine storm and decreasing the viral entry in PAH patients, others attributed it to PAH-specific medications that showed beneficial effects on COVID-19 pneumonia along with the anticoagulation used in chronic thromboembolic pulmonary hypertension (CTEPH) that reduced the prothrombotic mishaps of the virus [6–9].

Up to date, the available data regarding COVID-19 in pulmonary hypertension is limited, this lack of formal data available regarding COVID-19 infection in pulmonary hypertension (PH) patients, lead to limited scientific-based evidence to guide pulmonary hypertension providers to implement an efficient management approach, as well as to predict the disease course, hence improving survival [10].

This study is aiming to detect the incidence of COVID-19 infection among PH patients receiving specific therapy as well as the prognosticators of the COVID-19 disease severity and outcome in those patients.

Methodology
A retrospective cohort study of 21 PAH and CTEPH patients infected with COVID-19 seeking medical advice at the Pulmonary Hypertension Centre, Pulmonology Department, Kasr Al-Ainy Hospital from March 2020 to October 2021.

Patients infected with SARS-COV 2 proved positive via real-time polymerase chain reaction (RT-PCR) with or without radiological evidence of COVID-19 pneumonia were included in the study.

Demographic data, presenting symptoms, comorbidities, oxygen saturation, laboratory data, imaging results, medical treatments, hospitalization requirement, disease outcome (death or cure), and risk assessment of pulmonary hypertension during the last scheduled visit are collected from the medical records.

The research ethics committee, Cairo University, Egypt (N-3-2022) has reviewed and approved this study.

The World Health Organization (WHO) classifies COVID-19 severity into mild COVID-19-infected patients showing no clinical signs of pneumonia or hypoxemia, moderate COVID-19 patients showing clinical signs of pneumonia but no hypoxemia, severe COVID-19-infected patients showing clinical signs of severe pneumonia with respiratory rate more than 30 breaths/min, or severe respiratory distress; or hypoxemia with oxygen saturation less than 90% on room air and Critical COVID-19: patient with acute respiratory distress syndrome (ARDS) criteria, septic shock, or requires life-sustaining therapies as mechanical ventilation (invasive or non-invasive) or vasopressor therapy [11].

Pulmonary hypertension patients show an increase in the mean pulmonary artery pressure equal or more than 25 mmHg at rest when measured by the right heart catheter [12].

Assessing the risk in PH patients to estimate 1-year mortality using the prognostic determinants showing that patients with low risk have less than 5% 1-year mortality whereas patients with intermediate risk have from 5 to 10% 1-year mortality and patients with high risk have more than 10% 1-year mortality [12].

Data is collected in Excel sheet, tabulated, and statistically analyzed via SPSS version 21, qualitative data is presented by number and percentage, quantitative data is presented by mean and standard deviation.

Odds ratio is calculated, spearman correlation analysis is done, and chi-square test of significance is done for qualitative data.

Level of significance is set at $p$ equal to or below 0.05.

Results
A total of 197 PAH and CTEPH patients registered in the records of Pulmonary Hypertension Centre, Pulmonology Department, Kasr Al-Ainy Hospital, Cairo University, during the period of March 2020 to October 2021, that yielded 21 confirmed cases of COVID-19, with a percentage of 10.66%. Their mean age was 43.5 ± 11.07 (23-62). Other demographic data, characteristics, clinical presentations and lab findings of the studied patients are summarized in Tables 1 and 2.

There is no statistically significant relation between risk assessment in the last scheduled visit and the severity and outcome of COVID-19 as shown in Table 3.

The presence of fever, high serum ferritin, and d dimer levels had moderate positive significant correlation with the risk assessment of PH in the last scheduled visit as shown in Table 4.
The severity of COVID-19 disease in PH cases has statistically significant moderate to strong correlation with higher values of d-dimer, ferritin, and CRP, as well as hypoxemia and acute renal failure as shown in Table 5. The mortality of COVID-19 disease in our study population is 14.3%.

Mortality in COVID-19 PH cases has moderate to strong statistically significant correlations with

---

**Table 1** Characteristics and clinical presentation of COVID-19-infected PH cases

| Variable                               | Frequency | %   |
|----------------------------------------|-----------|-----|
| Gender                                 |           |     |
| Male                                   | 6         | 28.6|
| Female                                 | 15        | 71.4|
| Comorbidities                          | 7         | 33.3|
| Chronic liver disease                  | 3         | 14.3|
| Diabetes mellitus                      | 1         | 4.8 |
| Hypothyroidism                         | 1         | 4.8 |
| Cardiac                                | 1         | 4.8 |
| Hypertension                           | 1         | 4.8 |
| complication Acute renal failure       | 2         | 9.5 |
| Pulmonary hypertension diagnosis       |           |     |
| Idiopathic PAH                         | 6         | 28.6|
| Schistosomiasis-PH                     | 4         | 19.0|
| CTEPH                                  | 4         | 19.0|
| CTD-PH                                 | 3         | 14.3|
| Porto-PH                               | 2         | 9.5 |
| Drug-induced PH                        | 1         | 4.8 |
| CHD (ES)                               | 1         | 4.8 |
| PPH-specific treatment regimen         |           |     |
| Dual therapy                           | 14        | 66.7|
| Triple therapy                         | 3         | 14.3|
| CCB                                    | 2         | 9.5 |
| No                                     | 2         | 9.5 |
| Immunosuppressive treatment            | 7         | 33.3|
| One drug (prednisolone)                | 4         | 19.2|
| Two drugs (prednisolone with another drug) | 2     | 9.5 |
| Three drugs (prednisolone with other drugs) | 1     | 4.8 |
| Anticoagulants                         |           |     |
| Yes                                    | 4         | 19.0|
| No                                     | 17        | 81.0|
| Symptoms                               |           |     |
| Fever                                  | 12        | 57.1|
| Dyspnea                                | 12        | 57.1|
| Dry cough                              | 13        | 61.9|
| Fatigue                                | 4         | 19.0|
| Headache                               | 3         | 14.3|
| Chest pain                             | 1         | 4.8 |
| Hypoxia                                | 6         | 28.6|
| Hospitalization                        | 7         | 33.3|
| Severity                               |           |     |
| Mild                                   | 8         | 38.1|
| Moderate                               | 7         | 33.3|
| Severe                                 | 2         | 9.5 |
| Critical                               | 4         | 19.0|
| Outcome                                |           |     |
| Cure                                   | 18        | 85.7|
| Death                                  | 3         | 14.3|

---

**Table 2** Laboratory findings of COVID-19-infected PH cases

| Lab findings: | Mean ± standard deviation | Range    |
|--------------|---------------------------|----------|
| TL           | 5.92 ± 2.75               | 2.2–12   |
| Lymphocytes  | 1.63 ± 0.59               | 0.86–2.9 |
| Neutrophil   | 3.85 ± 2.54               | 0.6–8.5  |
| Platelets    | 201.91 ± 58.35            | 93–351   |
| CRP          | 42.54 ± 52.14             | 1–167    |
| Ferritin     | 213.29 ± 294.66           | 6–1246   |
| D dimer      | 0.59 ± 0.37               | 0.12–1.4 |

---

**Table 3** Association between the risk stratification for mortality in PH patients and COVID-19 severity and outcome

| Risk assessment | Low risk | Intermediate risk | High risk | P value for chi square |
|-----------------|----------|-------------------|-----------|------------------------|
| Severity:       |          |                   |           |                        |
| Mild            | 2 (50.0%)| 4 (40.0%)         | 2 (28.6%) | 0.408                  |
| Moderate        | 1 (25.0%)| 5 (50.0%)         | 1 (14.3%) |                        |
| Severe          | 0 (0.0%) | 1 (10.0%)         | 1 (14.3%) |                        |
| Critical        | 1 (25.0%)| 0 (0.0%)          | 3 (42.8%) |                        |
| Outcome:        |          |                   |           |                        |
| Cure            | 3 (75.0%)| 10 (100.0%)       | 5 (71.4%) | 0.259                  |
| Death           | 1 (25.0%)| 0 (0.0%)          | 2 (28.6%) |                        |

There is no statistically significant relation between risk assessment in the last scheduled visit and the severity and outcome of COVID-19.

---

**Table 4** Correlation between risk stratification of PH in the last scheduled visit and COVID severity, outcome, fever, serum ferritin, and D dimer levels

| Risk assessment correlations | P value for correlation | Pearson r |
|------------------------------|-------------------------|-----------|
| COVID severity               | 0.210                   | 0.285     |
| Outcome                      | 0.636                   | 0.110     |
| Fever                        | 0.043                   | 0.446     |
| Ferritin                     | 0.050                   | 0.432     |
| D-dimer                      | 0.010                   | 0.548     |

Presence of fever, high serum ferritin, and d dimer levels had moderate positive significant correlation with risk assessment

---

The severity of COVID-19 disease in PH cases has statistically significant moderate to strong correlation with higher values of d-dimer, ferritin, and CRP, as well as hypoxemia and acute renal failure as shown in Table 5. The mortality of COVID-19 disease in our study population is 14.3%.
hypoxemia, acute renal failure, higher values of ferritin, and d-dimer as shown in Table 5.

Mortality among COVID-19 PH cases has statistically significant odds ratio with fever, absence of fatigability, hypoxemia, and hospitalization as well as patients who did not receive prednisolone as shown in Table 6.

**Discussion**

The incidence of COVID-19 infection among our study population is 10.66%. (106.6 case per 1000 patients) which when compared to the incidence of COVID-19 infection in the general Egyptian population during the same period (3.3 per 1000) confirms a higher rate of COVID-19 infection among PAH and CTEPH patients [13].

This might be partially explained by realizing that PAH and CTEPH patients are more in contact with the health care system and are medically educated enough to seek help upon recognizing any new symptom, so the probability of them being tested at a higher rate as compared to the general population is present.

Our finding refuted prior studies that reported a relatively limited or similar incidence of COVID-19 infection in comparison to the general population [10, 14].

These studies were conducted in the early phases of the pandemic when both medical knowledge and widespread COVID-19 testing were lacking as well as home isolation and the disrupted follow-up to the patients, all contributing to the underestimation of cases [15].

The authors also noted that morbidity and mortality are discreetly worse in our study population with case fatality rate of 14.3% and hospitalization rate of 33.3% denoting unfavorable disease outcome.

These findings echo the latest reports published via Belge et al. and Lee et al., both reported high COVID-related mortality of 19% and 12% respectively in PAH and CTEPH patients along with higher rates of hospitalization of 70% and 30% respectively [10, 14].

Also, a retrospective study on PAH patients suffered from COVID-19 reported an unusually high mortality rate of 36.36% and hospitalization rate of 81.81% [16].

Comparing the mortality of COVID-19 disease in our study population (14.3%) from March 2020 to October 2021 to those reported for the Egyptian population at large (5.5%) during the same period, reinforces the allegation that PH is a risk factor of mortality in COVID-19 patients with a relative risk of 2.6 [13].

Our results contradict the earlier reports that suggested an attenuated disease course and favorable outcomes, assuming that specific pulmonary arterial hypertension therapy, low ACE2 levels, and anticoagulants provide protection from the pathological changes occurring from the disease [6–9].

These data are based on early information when the COVID-19 was still evolving, so thorough analysis to avoid misleading the pulmonary hypertension community should be done to prevent putting those patients in a greater risk.

Mortality in PH patients with COVID-19 infection is attributed to the observed pathophysiological impacts of the virus on different body organs.

**Table 5** Correlation between outcome and severity with other factors

| Factors                      | Severity | Mortality |
|------------------------------|----------|-----------|
| Ferritin                     | Pearson correlation r | .718 | .689 |
| Sig. (2-tailed)              | .000     | .001      |
| N                            | 21       | 21        |
| D dimer                      | Pearson correlation r | .821 | .603 |
| Sig. (2-tailed)              | .000     | .004      |
| N                            | 21       | 21        |
| CRP                          | Pearson correlation r | .613 | .279 |
| Sig. (2-tailed)              | .004     | .233      |
| N                            | 20       | 20        |
| Acute renal failure          | Pearson correlation r | .557 | .795 |
| Sig. (2-tailed)              | .009     | .000      |
| N                            | 21       | 21        |
| Hypoxemia                    | Pearson correlation r | .825 | .645 |
| Sig. (2-tailed)              | .000     | .002      |
| N                            | 21       | 21        |

**Table 6** Odds ratio for mortality among COVID-19 PH cases

| Variable                  | Death (n = 3) | Cure (n = 18) | Odds ratio | 95% CI          |
|---------------------------|--------------|--------------|------------|-----------------|
| Fever                     | 3            | 9            | 2.000      | 1.260–3.174     |
| Absence of fatigue        | 0            | 4            | 1.286      | 1.004–1.646     |
| Hypoxemia                 | 3            | 4            | 4.500      | 1.896–16.875    |
| Hospitalization           | 3            | 4            | 4.500      | 1.896–10.680    |
| Not receiving prednisolone| 3            | 11           | 1.636      | 1.132–2.366     |
Acute hypoxemic respiratory failure as a sequel to COVID-19 pneumonia in PH patients is a well-recognized outcome that in our experience so far, is associated with a more severe disease and increased mortality.

These findings echo the latest reports that management of COVID-19-infected PAH patients associated with hypoxemia is difficult [17] and that hypoxemia is associated with poor clinical outcomes [18, 19].

Petrilli et al. stated that impaired oxygen status upon hospital admission despite supplemental oxygen is present among the critically ill patients and is coupled with increased mortality [20].

Moreover, hypoxemia might overload the already compromised right ventricle in a patient with decreased cardiorespiratory reserve predisposing to right heart failure [16].

Bearing in mind the risk of developing ARDS in the setting of pulmonary vascular disease as suggested via prior studies [21, 22], posits hypoxemia as a potential predictor of a COVID-19 pneumonia in those group of patients and its existence might be fatal.

Even though the pathogenesis of COVID-19-induced acute kidney injury is still not precisely clear, yet several underlying mechanisms including direct viral injury, ischemia-reperfusion insults, unwarranted cytokine release, thrombotic events, and drug-induced renal injuries have been recognized [23].

Several prior studies have already identified renal failure as a risk factor associated with increased mortality in patients with sepsis and septic shock irrespective of the etiological cause [24, 25].

Our finding that acute renal failure escalates disease severity and its existence among critically ill COVID-19 patients is associated with increased mortality is consistent with other report [26].

Prior studies established that advanced age [1, 27] and male gender [28] are more prone to adverse outcome. Our participants are younger, 43.5 years old at mean age, and mostly females (71.4%); this might justify our findings that despite the higher incidence of the disease in this study population yet more than two thirds of the cases have mild and moderate COVID-19 disease.

In this study, only 19% of our patients presented with critical illness, this percentage is higher when compared to the multicenter retrospective study, performed on 2724 COVID-19 patients, of whom 423 (15.52%) were critically ill, denoting that PH is a risk factor contributing to COVID-19 disease severity [29].

Higher level of D-dimer is a pivotal predictor of disease severity and mortality indicating that the severe inflammation triggered in the critically ill COVID-19 patients [30] results in extensive coagulopathy [31] thus raising the D-dimer level via widespread thrombin generation and fibrinolysis [32].

Our analysis demonstrates a significant increase in the D-dimer levels in the severe and critically ill COVID-19 patients and that disease mortality is significantly associated with higher D-dimer levels.

These findings are in line with Tian et al and Zhou et al. found, both implied that elevated D-dimer level is associated with higher COVID-19 mortality [33, 34].

Also, Zhang et al. concluded that a fourfold increase in D-dimer level on hospital admission is a predictor of disease mortality in COVID-19 patients [35].

Recognizing the biomarkers that mirrors the level of inflammation, ferritin was first in line.

Our data suggests that higher ferritin levels are encountered in the severe and critically ill patients with higher mortality risk.

These results come in line with the meta-analysis conducted by Cheng et al. that revealed that elevated ferritin level is coupled with unfavorable outcome [36].

Similarly, Para et al. states that higher ferritin level is associated with the COVID-19 disease progression [37], advocating that inflammation generates higher ferritin levels that in turn promotes a cascade of events enhancing additional tissue damage [38].

Likewise, it is observed in this study that the CRP level directly correlates with disease severity. Our results come in agreement with Malik et al., showing that the increase in the CRP level is coupled with a more severe disease [39]. Although elevated CRP level reflects the body’s inflammatory state indicating tissue injury, yet it is non-specific and may be ascribed to other causes as secondary bacterial infection [40].

Study limitations
Our study is limited by its retrospective nature and limited sample size so predicting factors affecting severity and outcome is not possible due to our limited number of observations.

Conclusions
COVID-19 in PAH and CTEPH patients is challenging, higher COVID-19 infection rate is present in those patients and is associated with increased disease severity and higher mortality.

Abbreviations
ACE2: Angiotensin-converting enzyme 2; ARDS: Acute respiratory distress syndrome; COVID-19: Coronavirus disease 2019; CRP: C-reactive protein; CTEPH: Chronic thromboembolic pulmonary hypertension; PAH: Pulmonary arterial hypertension; PH: Pulmonary hypertension; RT-PCR: Real-time polymerase chain reaction; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; WHO: World Health Organization.
Acknowledgements
Not applicable

Authors’ contributions
YS and RE collected the patient’s data and were a major contributor in writing the manuscript. SM made substantial contributions to the conception and design of the work, collected the patient’s data, and was a major contributor in writing the manuscript. A Abdelnaby analyzed and interpreted the patient’s data. A AbdelAziz collected the patient’s data and contributed to writing the manuscript. All authors revised the article critically for important intellectual content. All authors read and approved the final manuscript to be published.

Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Declarations

Ethics approval and consent to participate
The research ethics committee, Cairo University, Egypt (N-3-2022) has reviewed and approved this study.

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Chest Diseases, Faculty of Medicine, Cairo University, Cairo 11562, Egypt. 2 National Heart Institute, Giza, Egypt. 3 Public Health, Faculty of Medicine, Cairo University, Cairo 11562, Egypt.

Received: 29 May 2022 Accepted: 19 October 2022
Published online: 05 November 2022

References
1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(10223):497–506
2. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, Bi Z, Zhao Y (2020) Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol 109(5):531–538
3. Sanyauoa A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, Hosein Z, Padda I, Mangat J, Altar M (2020) Comorbidity and its impact on patients with COVID-19. SN Comprehens Clin Med 2(8):1069–1076
4. Wright SP, Groves L, Vishram-Nielsen JK, Karvasarski E, Valle FH, Alba AC, Mak S (2020) Elevated pulmonary arterial elastance and right ventricular uncoupling are associated with greater mortality in advanced heart failure. J Heart Lung Transplant 39(7):657–665
5. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu H, Shan H, Lei CL, Hui DS, Du B. (2020) Clinical characteristics of coronavirus disease 2019 in China. New Engl J Med 382(18):1708–1720
6. Fernandes TM, Papamatheakis DG, Poch DS, Kim NH (2020) Letter to the Editor regarding “Could pulmonary arterial hypertension patients be at lower risk from severe COVID-19?”. Pulm Circ 10(2):2045894020925761
7. Sciri P, Iacovoni A, Abete R, Cereda A, Grosu A, Senni M (2020) An unexpected recovery of patients with pulmonary arterial hypertension and SARS-CoV-2 pneumonia: a case series. Pulmonary Circ 10(2):2045894020956581
8. Nuche J, Pérez-Olivares C, de la Cal TS, López-Guarch CJ, Ynsaurriaga FA, Subías PE (2020) Clinical course of COVID-19 in pulmonary arterial hypertension patients. Revista Espanola de Cardiologia (English ed) 73(9):775
9. Nuche J, Segura de la Cal T, Jiménez López Guarch C, López-Medrano F, Delgado CP, Ynsaurriaga FA, Delgado JF, Ibañez B, Oliver E, Subías PE (2020) Effect of Coronavirus Disease 2019 in Pulmonary Circulation. The particular scenario of precapillary pulmonary hypertension. Diagnostics 10(8):548
10. Belge C, Quarc R, Godinas L, Montani D, Subias PE, Vachiery JL, Nashat H, Peppe-Kaza J, Humbert M, Delcroix M (2020) COVID-19 in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a reference centre survey. ERJ Open Res 6(4)
11. WHO. Living guidance for clinical management of COVID-19. https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-2. Date last updated November 23, 2022. Accessed 17 May 2022
12. Galie N, Humbert M, Vachiery JL et al (2016) 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37:67–119
13. The WHO Global Health https://covid19.who.int/region/emro/country/eg. Date last updated April 23, 2022. Date Accessed: 17 May 2022
14. Lee JD, Burger CD, Delossantos GB, Grimnan D, Ralph DD, Rayner SC, Ryan JJ, Saffar Z, Ventetuolo CE, Zamarian RT, Leary PJ (2020) A survey-based estimate of COVID-19 incidence and outcomes among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension and impact on the process of care. Ann Am Thorac Soc 17(12):1576–1582
15. Yogevasaran A, Gall H, Tello K, Grünig E, Xanthoulis P, Ewert R, Kamp JC, Ols-sen KW, Wißmüller M, Rosenkranz S, Klose H (2020) Impact of SARS-CoV-2 pandemic on pulmonary hypertension out-patient clinics in a multi-centre study. Pulm Circ 10(3):204589402041682
16. Sulica R, Cefal F, Motschwiller C, Fenton R, Barroso A, Stermann D (2021) COVID-19 in pulmonary artery hypertension (PAH) patients: observations from a large PAH center in New York City. Diagnostics. 11(1):128
17. Ryan JJ, Melendres-Groves L, Zamarian RT, Oudiz RJ, Chakinala M, Rosen-zweig EB, Gomberg-Maitland M (2020) Care of patients with pulmonary arterial hypertension during the coronavirus (COVID-19) pandemic. Pulmonary circulation 10(2):2045894020920153
18. Xie J, Covassinn N, Fan Z, Singh P, Gao W, Li G, Kara T, Somers VK (2020) Association between hypoxemia and mortality in patients with COVID-19. In Mayo Clinic Proceedings. 95(6):1138–1147. Elsevier.
19. Duan J, Wang X, Chi J, Chen H, Bai L, Hu Q, Han X, Wu H, Zhu L, Wang X, Li Y (2020) Correlation between the variables collected at admission and progression to severe cases during hospitalization among patients with COVID-19 in Chongqing. J Med Viral 92(11):2616–2622
20. Petrelli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y, Tobin KA, Cerfolio RJ, Francois F, Horvitz LI (2020) Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. bmj. 22:369
21. Price LC, Wort SJ (2017) Pulmonary hypertension in ARDS: inflammation matters! Thorax 72:396–397
22. Pandolfi R, Barreira B, Moreno E et al (2017) Role of acid sphingomyelini-nase and IL-6 as mediators of endotoxininduced pulmonary vascular dysfunction. Thorax 72:460–471
23. Raza A, Estepa A, Chan V, Jafari MS (2020) Acute renal failure in critically ill COVID-19 patients with a focus on the role of renal replacement therapy: a review of what we know so far. Cureus 12(6)
24. Oppert M, Engel C, Brunkhorst FM, Bogatshch K, Reinhardt K, Frei U, Eckardt KU, Loeffler M, John S (2008) German Competence Network Sepsis (SepsisNet) study: a reference centre survey. ERJ Open Res 6(4)
25. Neveu H, Kleinknecht D, Brivet F, Loirat PH, Landais P (1996) French study group on acute renal failure. Prognostic factors in acute renal failure due to severe sepsis and septic shock—a significant independent risk factor for mortality: results from the German Prevalence Study. Nephrol Dial Transplant 23(3):904–909
26. Neweau H, Kleinkecht D, Brivet F, Loirat PH, Landais P (1996) German Study on acute renal failure. Prognostic factors in acute renal failure due to sepsis. Results of a prospective multicentre study. Nephrol Dial Transplant 11(2):293–299
27. Stevens JS, King KL, Robbins-Juarez SY, Khairallah P, Toma K, Alvarado Verdugo H, Daniel E, Douglas D, Moses AA, Peleg Y, Starakiewicz P (2020) High rate of renal recovery in survivors of COVID-19 associated acute renal failure requiring renal replacement therapy. PLoS One 15(12):e0244131
27. Gallo Marin B, Aghagoli G, Lavine K, Yang L, Siff EJ, Chiang SS, Salazar-Mather TP, Dumenco L, Savaria MC, Aung SN, Flanagan T (2021) Predictors of COVID-19 severity: a literature review. Rev Med Virol 31(1):1–10
28. Zhang J, Yu M, Tong S, Liu LY, Tang LV (2020) Predictive factors for disease progression in hospitalized patients with coronavirus disease 2019 in Wuhan, China. J Clin Virol 127:104392
29. Omran D, Al Soda M, Bahbah E, Esmat G, Shousha H, Elgebaly A, Abdel Ghaffar A, Alsheiki M, El Sayed E, Afify S, Abdel HS (2021) Predictors of severity and development of critical illness of Egyptian COVID-19 patients: a multicenter study. PLoS One 16(9):e0256203
30. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermann R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H (2020) Endothelial cell infection and endotheliitis in COVID-19. Lancet. 395(10234):1417–1418
31. Marietta M, Ageno W, Artoni A, De Candia E, Gresele P, Marchetti M, Marcucci R, Tripodi A (2020) COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISTE). Blood Transfus 18(3):167
32. Matsuo T, Kobayashi H, Kario K, Suzuki S (2000) Fibrin D-dimer in thrombogenic disorders. In Seminars in thrombosis and haemostasis 26(01):101–107. https://doi.org/10.1055/s-2000-9811
33. Tian W, Jiang W, Yao J, Nicholson CJ, Li RH, Sigurslid HH, Woooster L, Rotter JI, Guo X, Malhotra R (2020) Predictors of mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis. J Med Virol 92(10):1875–1883
34. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 395:1054–1062
35. Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, Zhang Z (2020) D-dimer levels on admission to predict in-hospital mortality in patients with COVID-19. J Thromb Haemost 18(6):1324–1329
36. Cheng L, Li H, Li L, Liu C, Yan S, Chen H, Li Y (2020) Ferritin in the coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. J Clin Lab Anal 34(10):e23618
37. Para O, Caruso L, Pestelli G, Tangianu F, Carrara D, Maddaluni L, Tamburello A, Castelnuovo L, Fedi G, Guidi S, Pestelli C (2022) Ferritin as prognostic marker in COVID-19: the FerVid study. Postgrad Med 134(1):58–63
38. Kell DB, Pretorius E (2014) Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells. Metallomics. 6(4):748–773
39. Malik P, Patel U, Mehta D, Patel N, Kelkar R, Akrmah M et al (2021) Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. BMJ Evid Based Med 26(3):107–108
40. Stringer D, Braude P, Mynt PK et al (2021) The role of C-reactive protein as a prognostic marker in COVID-19. Int J Epidemiol 50(2):420–429

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.